MenQuadfi Earliest Age of Administration
MenQuadfi (MenACWY-TT) can be administered as early as 6 weeks of age 1.
FDA-Approved Dosing by Age
According to the FDA prescribing information, MenQuadfi is approved for individuals 6 weeks of age and older, with the following primary vaccination schedules 1:
Infants and Young Children
- 6 weeks to <2 months: First dose may be given as early as 6 weeks when starting the 4-dose series (at 2,4,6, and 12-18 months)
- 2 months: Standard 4-dose series at 2,4,6, and 12-18 months of age
- 6-11 months: 2-dose series with second dose in the second year of life, at least 3 months after first dose
- 12-23 months: 2-dose series with second dose at least 3 months after first dose
Children and Adults
- ≥2 years: Single dose for primary vaccination
ACIP Guideline Context
The 2020 ACIP guidelines confirm that MenACWY-TT (MenQuadfi) is licensed for persons aged ≥2 years for routine use 2. However, the FDA label extends approval down to 6 weeks of age, which represents the absolute earliest age for administration 1.
Important Clinical Considerations
For outbreak situations or high-risk populations, the vaccine can be initiated as early as 6 weeks, though ACIP guidelines primarily focus on routine recommendations starting at 2 months for infants at increased risk 2.
Key distinction from other MenACWY vaccines:
- MenACWY-D (Menactra): Licensed ≥9 months
- MenACWY-CRM (Menveo): Licensed ≥2 months
- MenACWY-TT (MenQuadfi): Licensed ≥6 weeks (earliest option)
Safety Data
Recent Phase III data support the safety profile of MenQuadfi in infants as young as 6 weeks when administered concomitantly with routine pediatric vaccines 3. The vaccine was well-tolerated with comparable safety profiles to other licensed meningococcal vaccines in this age group.
Bottom line: While routine ACIP recommendations typically begin at 2 months for at-risk infants, the FDA-approved earliest age for MenQuadfi administration is 6 weeks, making it the only MenACWY vaccine licensed for use this early in life.